What is CAR-T Therapy?
CAR-T therapy uses the power of your own immune system to fight blood cancers like lymphoma, leukemia, and myeloma. The process involves collecting a patient's own T-cells (a type of white blood cell), re-engineering them in a specialized manufacturing facility so they can better recognize and attack cancer cells.
These "supercharged" cells are then expanded into millions and re-infused into the patient. Once inside the body, CAR-T cells continue to hunt down cancer cells for months or even years.
1. COLLECTION
Patient's T-cells are collected through a process called apheresis
2. ENGINEERING
T-cells are re-engineered in the lab to better recognize cancer cells, then expanded into millions
3. RE-INFUSION
Enhanced CAR-T cells are returned to fight cancer for months or years
Cost in China vs Other Countries
CAR-T Therapy is exceptionally affordable in China, thanks to localized manufacturing of US pharma companies, and centralized national procurement program that negotiates down prices for patients.
United States
$400,000 - $500,000
Singapore
$300,000 - $400,000
China
$90,000 - $180,000
Why China Offers Better Value
-
>50% of the world's CAR-T clinical trials are conducted in China, creating deep expertise in many hospitals and doctors
-
Localized manufacturing by US biotech companies
-
Government centrally procure and negotiate down prices
80%
Cost Savings vs US
And higher efficacy and safety statistics
CART Products Overview
Advanced CAR-T therapies with superior efficacy and safety profiles
Axi-cel
Proven Track Record Since 2017
✓ Regulatory Approval
US FDA approved for LBCL and FL since 2017
🏭 Manufacturing
Kite Pharma (Gilead) & Fosun Pharma Joint Venture
Shanghai Manufacturing
📈 Efficacy
80%+ ORR
🛡️ Safety Profile
90%+ of patients developed only mild complications
⭐ Key Highlights
•First to market
•Extensive clinical data
•Proven safety profile
Relma-cel (Liso-cel)
Enhanced Long-term Efficacy
✓ Regulatory Approval
US FDA approved for LBCL, FL, CLL/SLL and MCL (2021-24)
🏭 Manufacturing
Juno Therapeutics (Bristol Myers Squibb) & WuXi AppTec
Shanghai Manufacturing (JW Therapeutics - HK Listed)
📈 Efficacy
~80% ORR
🛡️ Safety Profile
95% of patients developed only mild complications
⭐ Key Highlights
•Superior long-term outcomes
•Broader indications
•Public company backing
Zevor-cel
BCMA-directed Fully Human scFv
✓ Regulatory Approval
China NMPA approved for RRMM (2024), US FDA Phase II ongoing
🏭 Manufacturing
BCMA-directed fully human scFv technology
China-developed innovation
📈 Efficacy
>90% ORR, depth of response increasing with time
🛡️ Safety Profile
90% of patients experienced only mild complications
⭐ Key Highlights
•Fully human lentivirus
•Exceptionally high efficacy
•Increasing efficacy over time
Eque-cel
BCMA-directed
✓ Regulatory Approval
NMPA approved for RRMM (2023), US FDA IND ongoing
🏭 Manufacturing
IASO Biotherapeutics
China-developed Innovation
📈 Efficacy
95%+ ORR
🛡️ Safety Profile
90%+ of patients developed only mild complications
⭐ Key Highlights
•Fully human lentivirus
•Exceptionally high efficacy
•Increasing efficacy over time
Puzol-cel
Affordable option for children
✓ Regulatory Approval
NMPA approved for Pediatrics B-ALL (2025)
🏭 Manufacturing
Precision Biotech
China-developed Innovation
📈 Efficacy
>90% CR/CRi, >70% response maintained at 3 months
🛡️ Safety Profile
~70% of patients developed only mild complications
⭐ Key Highlights
•Most affordable pediatrics CAR-T
•High efficacy and long-lasting response
Pilot Use CAR-T
Latest technology in CAR-T
✓ Regulatory Approval
Post Phase II clinical trial with solid data. Approved for pilot use in selected leading hospitals only.
🏭 Manufacturing
Various biotech companies
China-developed innovation
📈 Efficacy
Generally similar ORR around 80%. New tech e.g. new antigen targets, and dual-target CAR-T promises more sustained long-term survival.
🛡️ Safety Profile
Generally safer due to usage of fully humanized viral vectors
⭐ Key Highlights
•Fully human design
•Latest technology
•Much more affordable than commercialized products
CAR-T Patient Journey
1-2 overseas trips, 4-6 weeks in total
1
Assessment & Apheresis
Pre-assessment and apheresis to collect T-cells
2
Engineering & Expansion
Return home while T-cells are engineered and expanded in the manufacturing facility
3
Infusion & Monitoring
CAR-T cell infusion with inpatient monitoring and complication management
Total Treatment Period
7-9 weeks
Exact duration depending on the degree of complication management required